LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.

Trial Details

NCT ID

NCT06387628

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

LM-108
Toripalimab
Eribulin
Nab paclitaxel

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Age 18-75 years old (including boundary value), no gender limit;
ECOG score 0-1;
Expected survival ≥3 months;
Unresectable or metastatic or postoperative recurrent, histologically confirmed advanced triple-negative breast cancer. Triple-negative breast canc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →